The use of growth hormone and insulin-like growth factor-I in catabolic states

Journal of Pediatric Endocrinology and Metabolism

Volumn 10, Issue SUPPL. 1, 1997, Pages 131-136

  Jenkins, Richard C ^a   Ross, Richard J M ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

catabolism; growth hormone; insulin like growth factor I

Indexed keywords

GLUCOSE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

CATABOLISM; CONFERENCE PAPER; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; HORMONE RESISTANCE; HYPOGLYCEMIA; HYPOPHYSIS; LARON SYNDROME; NITROGEN BALANCE; NUTRITION; PROTEIN SYNTHESIS;

EID: 0030976171     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/jpem.1997.10.s1.131     Document Type: Conference Paper

References (44)

1. Ziegler TR, Gatzen C, Wilmore DW. Strategies for attenuating protein-catabolic responses in the critically ill. Ann Rev Med 1994; 45: 459-480.
2. Strobl JS, Thomas MJ. Human growth hormone. Pharmacol Rev 1994; 46: 1-34.
3. Ghigo E, Arvat E, Gianotti L, et al. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal and oral administration in man. J Clin Endocrinol Metab 1994; 78: 693-698.
4. Jenkins RC, Ross RJM. Acquired growth hormone resistance in catabolic states. Bailliere's Clinical Endocrinology and Metabolism 1996; 10: 411-419.
5. Koea JB, Galagher BM, Breier BH. Passive immunisation against circulating insulin-like growth factor-I increases protein catabolism in lambs: evidence for a physiological role for circulating IGF-I. J Endocrinol 1992; 135: 279-284.
6. Voerman HJ, Strack van Schijdel RJM, Groeneveld ABJ, et al. Effects of recombinant human growth hormone in patients with severe sepsis. Ann Surg 1992; 216: 648-655.
7. Ponting GA, Halliday D, Teale JD, Sim AJW. Post-operative positive nitrogen balance with intravenous hyponutrition and growth hormone. Lancet 1988; i: 438-440.
8. Ward HC, Halliday D, Sim AJW. Protein and energy metabolism with biosynthetic human growth hormone after gastrointestinal surgery. Ann Surg 1987; 206: 56-61.
9. Wilmore DW, Moylan JA, Bristow BF, Mason AD, Pruitt BA. Anabolic effects of human growth hormone and high caloric feedings following thermal injury. Surg Gynecol Obstet 1974; 138: 875-884.
10. Jeevanandam M, Ali MR, Holaday NJ, Petersen SR. Adjuvant recombinant human growth hormone normalizes plasma amino acids in parenterally fed trauma patients. J Parenter Enterai Nutr 1995; 19: 137-144.
11. Suchner U, Rothkopf MM, Stanislaus G, Elwyn DH, Kvetan V, Askanazi J. Growth hormone and pulmonary disease: Metabolic effects in patients receiving parenteral nutrition. Arch Intern Med 1990; 150: 1225-1230.
12. Ziegler TR, Rombeau JL, Young LS, et al. Recombinant human growth hormone enhances the metabolic efficacy of parenteral nutrition: a double-blind, randomized controlled study. J Clin Endocrinol Metab 1992; 74: 865-873.
13. Mulligan K, Grunfeld C, Hellerstein MK, Neese RA, Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1993; 77: 956-962.
14. Byrne TA, Morrissey TB, Gatzen C, et al. Anabolic therapy with growth hormone accelerates protein gain in surgical patients requiring nutritional rehabilitation. Ann Surg 1993; 218: 400-416.
15. Wolf RF, Pearlstone DB, Newman E, et al. Growth hormone and insulin reverse net whole body and skeletal muscle protein catabolism in cancer patients. Ann Surg 1992; 216: 280-288.
16. Douglas RG, Humberstone DA, Haystead A, Shaw JHF. Metabolic effects of recombinant human growth hormone: isotopic studies in the postabortive state and during total parenteral nutrition. Br J Surg 1990; 77: 785-790.
17. Horber FF, Raymond MW. Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J Clin Invest 1990; 86: 265-272.
18. Bennet WM, Haymond MW. Growth hormone and lean tissue catabolism during long-term glucocorticoid treatment Clin Endocrinol Oxf 1992; 36: 161-164.
19. Jiang Z, He G, Zhang S, et al. Low-dose growth hormone and hypocaloric nutrition attenuate the protein-catabolic response after major operation. Ann Surg 1989; 210: 513-525.
20. Gore DC, Honeycutt D, Jahoor F, Wolfe RR, Herndon DN. Effect of exogenous growth hormone on whole-body and isolated-limb protein kinetics in burned patients. Arch Surg 1991; 126: 38-43.
21. Hammarqvist F, Stromberg C, Von Der Decken A, Vinnars E, Wernerman J. Biosynthetic human growth hormone preserves both muscle protein synthesis and the decrease in muscle-free glutamine, and improves whole-body nitrogen economy after operation. Ann Surg 1992; 216: 184-191.
22. Knox J, Demling R, Wilmore D, Sarraf P, Santos A. Increased survival after major thermal injury: the effect of growth hormone therapy in adults. J Trauma 1995; 39: 526-530.
23. Herndon DN, Barrow RE, Kunkel KR, Broemeling L, Rutan RL. Effects of recombinant human growth hormone on donor-site healing in severely burned children. Ann Surg 1990; 212: 424-429.
24. Vara-Thorbeck R, Guerrero JA, Rosell J, Ruiz-Requena E, Capitan JM. Exogenous growth hormone: Effects on the catabolic response to surgically produced acute stress and on post-operative immune function. World J Surg 1993; 17: 530-538.
25. Hill GL. Invited Commentary. World J Surg 1993; 17: 537-538.
26. Tayek JA, Brasel JA. Failure of anabolism in malnourished cancer patients receiving growth hormone: A clinical research center study. J Clin Endocrinol Metab 1995; 80: 2082-2087.
27. Pape GS, Friedman M, Underwood LE, Clemmons DR, The effect of growth hormone on weight gain and pulmonary function in patients with chronic obstructive lung disease. Chest 1991; 99: 1495-1500.
28. Pichard C, Kyle U, Chevrolet J, et al. Lack of effects of recombinant growth hormone on muscle function in patients requiring prolonged mechanical ventilation: A prospective, randomized controlled study. Crit Care Med 1996; 24: 403-413.
29. Gottardis M, Benzer A, Koller W, Luger TJ, Puhringer F, Hackl J. Improvement of septic syndrome after administration of recombinant human growth hormone? J Trauma 1991; 31: 81-86.
30. Knox JB, Demling RH, Wilmore DW, Sarraf P, Santos AA. Hypercalcemia associated with the use of human growth hormone in an adult surgical intensive care unit Arch Surg 1995; 130: 442-445.
31. Laron Z, Klinger B. Laron syndrome: clinical features, molecular pathology and treatment. Horm Res 1994; 42: 198-202.
32. Fouque D, Peng SC, Kopple JD. Pharmacokinetics of recombinant human insulin-like growth factor-1 in dialysis patients. Kidney Int 1995; 47: 869-875.
33. Clemmons DR, Smith Banks A, Underwood LE. Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I in humans. J Clin Endocrinol Metab 1992; 75: 234-238.
34. Miell JP, Taylor AM, Jones J, et al. Administration of human recombinant insulin-like growth factor-I to patients following major gastrointestinal surgery. Clin Endocrinol Oxf 1992; 37: 542-551.
35. Laager R, Ninnis R, Keller U. Comparison of the effects of recombinant human insulin-like growth factor-I and insulin on glucose and leucine kinetics in humans. J Clin Invest 1993; 92: 1903-1909.
36. Mauras N, Horber FF, Raymond MW. Low dose recombinant human insulin-like growth factor-I fails to affect protein anabolism but inhibits islet cell secretion in humans [see comments]. J Clin Endocrinol Metab 1992; 75: 1192-1197.
37. Coiffi WG, Gore DC, Rue LW, et al. Insulin-like growth factor-I lowers protein oxidation in patients with thermal injury. Ann Surg 1994; 220: 310-319.
38. Mauras N, Beaufrere B. Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisone in humans without a diabetogenic effect. J Clin Endocrinol Metab 1995; 80: 869-874.
39. Sandstrom R, Svanberg E, Hyltander A, et al. The effect of recombinant human IGF-I on protein metabolism in post-operative patients without nutrition compared to effects in experimental animals. European Journal of Clinical Investigation 1995; 25: 784-792.(Abstract)
40. Lieberman SA, Butterfield GE, Harrison D, Hoffman AR. Anabolic effects of recombinant insulin-like growth factor-I in cachetic patients with the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1994; 78: 404-410.
41. Goeters C, Mertes N, Tacke J, et al. Repeated administration of recombinant human insulin-like growth factor-I in patients after gastric surgery. Ann Surg 1995; 222: 646-653.
42. Kupfer SR, Underwood LE, Baxter RC, Clemmons DR. Enhancement of the anabolic effects of growth hormone and insulin-like growth factor-I by use of both agents simultaneously. J Clin Invest 1993; 91: 391-396.
43. Mauras N. Combined recombinant human growth hormone and recombinant human insulin-like growth factor I: lack of synergy on whole body protein anabolism in normally fed subjects. J Clin Endocrinol Metab 1995; 80: 2633-2637.
44. Ross RJ, Wilmore D. Endocrinology in catabolic illness. Endocrinol Metab 1996; 3 (Suppl A): 115-118.